HI
CRVS icon

HBK Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

HBK Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-120,000
Closed -$1.74M – 979
2016
Q1 		$1.74M Buy
+120,000
New +$1.72M 0.02% 463

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

HBK Investments's CRVS Position: Q2 2016 in Review

HBK Investments sold out of Corvus Pharmaceuticals (CRVS) in Q2 2016, closing a stake of 120,000 shares — an estimated $1.74M sold.

HBK Investments first reported a position in CRVS in Q1 2016 and held it in 1 quarter. The position peaked at $1.74M in Q1 2016. 45 funds tracked by Wall St. Rank hold CRVS as of Q2 2016.

  • HBK Investments reported no remaining Corvus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • HBK Investments sold 120,000 Corvus Pharmaceuticals shares in Q2 2016, an estimated $1.74M.
  • HBK Investments first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • HBK Investments's Corvus Pharmaceuticals position peaked at $1.74M in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2016.

Based on HBK Investments's 13F filing for Q2 2016, filed 15 Aug 2016.